Aquinox Pharmaceuticals logo — Discovering and developing small molecule therapeutics to tr...

Aquinox Pharmaceuticals

Discovering and developing small molecule therapeutics to treat cancer and inflammatory diseases since 2004

Founded 2004 Post-IPO Equity Total: $221.39M Biotechnology, Health Care +1

General Information

Company Name Aquinox Pharmaceuticals
Founded Year 2004
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Aquinox Pharmaceuticals. To contact Aquinox Pharmaceuticals, visit aqxpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Aquinox Pharmaceuticals compare?

A PDF of Aquinox Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Aquinox Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals Inc. is a Vancouver-based pharmaceutical company that has been dedicated to discovering and developing small molecule therapeutics since its establishment in 2004. With a focus on treating cancer and inflammatory diseases, the company's product portfolio includes AQX-MN100, a medication designed for these purposes. Additionally, Aquinox has a SH2-containing inositol 5'-phosphatase inhibition program aimed at aiding in blood cell recovery. The company received a significant $75.40M Post-IPO Equity investment on 20 September 2016. As the company operates in the Biotechnology, Health Care, and Health and Wellness industries, its innovative approach to treating critical diseases presents a compelling opportunity for investors seeking to support breakthrough advancements in the healthcare sector.

Business keywords: pharmaceuticals, small molecule therapeutics, cancer treatment, inflammatory disease treatment, AQX-MN100, SH2-containing inositol 5'-phosphatase inhibition program, drug development, bio-pharmaceuticals, cancer therapy, blood cell recovery, Vancouver, Canada

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $75.40M -
20 Sep 2016
Post IPO Equity $75.40M 1
Cowen Group
15 Sep 2015
Series C $18.00M 6
Ventures West, Augment Investments +4
03 Apr 2013
Venture Round $3.54M -
21 Sep 2011
Venture Round $4.72M -
12 Feb 2011
Series B $25.00M 5
Ventures West, BC Advantage Funds +3
17 Jun 2010
Venture Round $4.83M -
15 Apr 2010
Series A $14.50M 4
Ventures West, BC Advantage Funds +2
12 Jun 2007

Aquinox Pharmaceuticals Alternatives & Competitors

View All Alternatives
Aquinox Pharmaceuticals vs

Innovating patient care with advanced small molecule therapies for severe medical conditions, includ...

Post-IPO Equity
Biotechnology, Health Care
Aquinox Pharmaceuticals vs
858 Therapeutics
858 Therapeutics United States

Discovering innovative small molecule therapeutics for the treatment of cancer

Venture round
30 employees
Biotechnology, Health Care
Aquinox Pharmaceuticals vs

Pioneering Therapeutics to Combat Inflammatory Diseases, Pioneering Better Health

Post-IPO Equity
Biotechnology, Health Care

FAQ About Aquinox Pharmaceuticals

Discovering and developing small molecule therapeutics to treat cancer and inflammatory diseases since 2004
Aquinox Pharmaceuticals was founded in 2004.
Aquinox Pharmaceuticals operates in Biotechnology, Health Care and Health and Wellness. Its work centres on pharmaceuticals, small molecule therapeutics, cancer treatment and inflammatory disease treatment.
Aquinox Pharmaceuticals has completed 8 funding rounds, raising a total of $221.39M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Aquinox Pharmaceuticals include Synta Pharmaceuticals, 858 Therapeutics, Anthera Pharmaceuticals, InflaRx, ProteoTech. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Aquinox Pharmaceuticals and Synta Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Aquinox Pharmaceuticals, https://bouncewatch.com/company/aquinox-pharmaceuticals, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes